Literature DB >> 6762484

Paget's disease: improvement of spinal cord dysfunction with diphosphonates and calcitonin.

D L Douglas, J A Kanis, T Duckworth, D J Beard, A D Paterson, R G Russell.   

Abstract

The clinical and radiographic features of spinal cord dysfunction secondary to Paget's disease are described. Long-term medical management with the use of the diphosphonates, calcitonins and mithramycin resulted in marked and rapid clinical improvements in 8 of 10 of our own patients. These results are comparable to those seen in 19 other patients previously described in the literature, and are also similar to those obtained by surgical treatment. The recurrence rate and mortality (approximately 10%) of surgical treatment suggest that drug treatment now has a place in the management of paraparesis, particularly when this is of gradual onset. Medical management may also provide a valuable adjunct in those cases where surgery is required (e.g. sudden onset of paraparesis). In patients with cord dysfunction, but without significant anatomical compression of the spinal cord, it is suggested that paraparesis may be caused by a "vascular steal" syndrome, a notion which is supported by the rapidity with which drug-induced remission occurs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6762484     DOI: 10.1016/0221-8747(81)90049-7

Source DB:  PubMed          Journal:  Metab Bone Dis Relat Res        ISSN: 0221-8747


  4 in total

Review 1.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Treating Paget's disease.

Authors:  D A Heath
Journal:  Br Med J (Clin Res Ed)       Date:  1987-04-25

3.  Treating Paget's disease.

Authors:  J A Kanis; R E Gray; E V McCloskey
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-20

4.  Paget's disease of bone. An update on management.

Authors:  D J Hosking
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.